ERBB2 and ovarian carcinoma: In a separate phase I study, peptides targeting HER2/neu, human telomerase reverse transcriptase (hTERT) and pan-DR epitope (PADRE) were combined with dendritic cells, isolated from ovarian cancer patients, to be used as a vaccine [72].